Medindia
About ▼ Careers Internship MedBlog Contact us
English (US) ▼
Medindia
LOGIN REGISTER
Advertisement

The Launch of Eight Novel Disease-Modifying Therapies, Including the First Oral Agents Approved for the Indication, Will Drive Modest Growth in the Multiple Sclerosis Drug Market Through 2019

Monday, July 12, 2010 Drug News
Advertisement
Novartis/Mitsubishi Tanabe Pharma's FTY-720 and Merck Serono/EMD Serono's Oral Cladribine Will Have the Most Significant Market Impact, According to Findings from Decision Resources

For more information, contact:

Decision Resources, Inc.

Christopher Comfort

781-296-2597

[email protected]

Sponsored Post and Backlink Submission


Latest Press Release on Drug News

London Research & Pharmaceuticals presents the Advancement of LRP-661, their Oral Cannabidiol Sulphate Drug Candidate at the Prestigious Epilepsy Therapies & Diagnostics Development (ETDD) XVII Conference in Miami
LONDON, Ontario, April 15, 2024 (GLOBE NEWSWIRE) -- London Research & Pharmaceuticals has recently publicized data about its lead compound LRP-661 or Cannabidiol sulphate (CBDS), hig...
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection
Provides MarVax™ Heat Stable Vaccine Seven Years of U.S. Market Exclusivity Upon FDA Approval  PRINCETON, N.J. , April 15, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq...
SparX Group Announces First Patient Dosed with SPX-303 Injection, the First in Its Class of anti-LILRB2/PD-L1 Bispecific Antibody Drugs
CHICAGO , April 11, 2024 /PRNewswire/ -- Signifying a monumental step forward in the domain of powered antibody therapies, SparX is thrilled to announce that the first patient has bee...
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection
Provides SuVax™   Heat Stable Vaccine Seven Years of U.S. Market Exclusivity Upon FDA Approval PRINCETON, N.J. , April 11, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: S...
Sen-Jam Pharmaceutical Partners with Specialty Pharmaceutical Manufacturer to Provide Formulation and Chemistry, Manufacturing & Controls for Revolutionary Anti-Inflammatory Injectable
Sen-Jam Pharmaceutical has entered their third development, manufacturing, distribution and license agreement with KVK-Tech. This is a monumental milestone for the company and great n...
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close